Table 1.
Patient demographics.
| Total (n = 92) | Adherent (n = 33) | Non-adherent (n = 59) | P | |
|---|---|---|---|---|
| Age at transplant, year, median (IQR) | 43 (18–67) | 43 (21–67) | 43 (18–58) | .078 |
| Length of time post-transplant, year (IQR) | 1.8 (1.1–3.7) | 1.7 (1.1–3.2) | 1.8 (1.1–3.9) | .663 |
| Sex, male (%) | 58 (63.0) | 22 (66.7) | 36 (61.0) | .590 |
| BMI, mean (SD), kg/m2 | 22.0 (3.1) | 21.9 (3.3) | 22.1 (3.0) | .801 |
| Education (%) | .828 | |||
| Undergraduate college | 46 (50.0) | 16 (48.5) | 30 (50.8) | |
| Graduate college | 46 (50.0) | 17 (51.5) | 29 (49.2) | |
| Donor type (%) | .904 | |||
| Deceased | 37 (40.2) | 13 (39.4) | 24 (40.7) | |
| Living | 55 (59.8) | 20 (60.6) | 35 (59.3) | |
| Immunosuppressive (%) | ||||
| MMF | 86 (93.5) | 30 (90.9) | 56 (94.9) | .455 |
| Prednisone | 86 (93.5) | 31 (93.9) | 55 (93.2) | .893 |
| Daily tacrolimus dose, mean ± SD, mg | ||||
| At enrollment | 4.5 ± 2.4 | 4.1 ± 1.7 | 4.7 ± 2.6 | .229 |
| At last visit | 4.1 ± 2.1 | 3.9 ± 1.7 | 4.3 ± 2.3 | .292 |
| Trough concentration (C0) of tacrolimus, mean ± SD, ng/mL | ||||
| At enrollment | 5.8 ± 1.8 | 6.4 ± 2.2 | 5.4 ± 1.5 | .008 |
| At last visit | 5.8 ± 1.6 | 6.0 ± 1.5 | 5.7 ± 1.7 | .302 |
| MEMS, median (IQR), % | ||||
| Taking adherence | 96.3 (77.7 – 99.5) | 99.7 (99.2 – 100.0) | 86.0 (63.9 – 95.9) | < .001 |
| Dosing adherence | 89.7 (65.2 – 97.0) | 97.8 (95.9 – 99.5) | 72.5 (53.3 – 89.8) | < .001 |
| Timing adherence | 90.9 (61.6 – 98.0) | 98.1 (96.5 – 99.3) | 73.5 (50.0 – 90.1) | < .001 |
| TTR, median (IQR) | 47.7 (17.5 – 76.5) | 50.1 (17.5 – 82.3) | 43.1 (14.9 – 71.0) | .552 |
IQR, interquartile range; BMI, body mass index; SD, standard deviation; MMF, mycophenolate mofetil; MEMS, medication event monitoring system; TTR, time in therapeutic range.